<DOC>
	<DOCNO>NCT01988662</DOCNO>
	<brief_summary>This study assess systemic vascular endothelial growth factor ( VEGF ) level patient neovascular Age-related Macular Degeneration follow treatment Ranibizumab Aflibercept . Free plasma VEGF-A level measure study .</brief_summary>
	<brief_title>UNcovering Difference Between Ranibizumab Aflibercept , Focusing Systemic Anti-vascular Endothelial Growth Factor ( VEGF ) Effects Patients With neovascuLar Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Key Inclusion Criteria Newly diagnose Agerelated Macular Degeneration ( AMD ) No previous treatment receive diagnosed AMD Visual Acuity 6/7.5 6/96 Key standard exclusion criterion antiVEGF treatment Visual Acuity &lt; 6/96 nAMD eye , condition eye may require anti VEGF treatment study period disease candidate eye could compromise visual acuity require medical/surgical intervention study period participation clinical study 'not approve ' treatment within year prior UNRAVEL study participation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nAMD , VEGF , VEGF agent , BCVA , CRT , Ranibizumab , Lucentis , Aflibercept , Eylea</keyword>
</DOC>